News

News 20.08.2025 Schlieren / Zurich, Switzerland, 19 August, 2025 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, has published Phase I clinical data in Clinical and Translational Science, highlighting the safety, tolerability, and pharmacokinetics (PK) of its lead clinical asset, potravitug,...

News 14.08.2025 Schlieren (Zurich), Switzerland, August 14, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced its financial and operational results for the first half of 2025, demonstrating continued momentum in growth, broader market reach, and progress on key strategic priorities. Total group revenue...

News 12.08.2025 Schlieren/Zurich, Switzerland, August 12, 2025 - Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has raised a total of CHF 30 million (USD 37 million) to further develop its clinical-stage lead candidate MY006 and advance its early-stage pipeline. The funding combines a...

News 12.08.2025 Topadur Pharma AG, a Swiss biopharmaceutical company developing innovative therapies for aging-related diseases, announces the appointment of Professor Thierry Carrel, MD, to its Board of Directors. Professor Carrel is one of Switzerland’s most accomplished cardiac surgeons. His expertise in clinical needs, regulatory navigation, and innovative technologies will provide strategic direction...

News 05.08.2025 Schlieren (Zürich), Switzerland, August 5, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced the completion of the first U.S. cases using the new MagnetOsTM MIS Delivery System – a sterile, prefilled, single-use delivery system engineered for Minimally Invasive Surgery (MIS) in spine...